Inventor

SUBRAMANIAN ROMESH R

US58 patents

Patents

50 patents

US11286305B2Mar 29, 2022

Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA

DYNE THERAPEUTICS INC64 citations99

US11111309B2Sep 7, 2021

Method of reducing expression of DUX4 in a muscle cell by administering an anti-transferrin receptor antibody linked to an oligonucleotide targeting DUX4

DYNE THERAPEUTICS INC65 citations99

US11833217B2Dec 5, 2023

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC30 citations98

US11795233B2Oct 24, 2023

Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oligonucleotide

DYNE THERAPEUTICS INC32 citations98

US11795234B2Oct 24, 2023

Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

DYNE THERAPEUTICS INC32 citations98

US11787869B2Oct 17, 2023

Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy or a disease associated with muscle weakness

DYNE THERAPEUTICS INC32 citations98

US11771776B2Oct 3, 2023

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC32 citations98

US11759525B1Sep 19, 2023

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC32 citations98

US11679161B2Jun 20, 2023

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC38 citations98

US11672872B2Jun 13, 2023

Anti-transferrin receptor antibody and uses thereof

DYNE THERAPEUTICS INC37 citations98

US11648318B2May 16, 2023

Anti-transferrin receptor (TFR) antibody and uses thereof

DYNE THERAPEUTICS INC37 citations98

US11638761B2May 2, 2023

Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC47 citations98

US11633496B2Apr 25, 2023

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC36 citations98

US11518816B2Dec 6, 2022

Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC46 citations98

US11497815B2Nov 15, 2022

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC46 citations98

US11390682B2Jul 19, 2022

Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy

DYNE THERAPEUTICS INC48 citations98

US11369689B2Jun 28, 2022

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy

DYNE THERAPEUTICS INC11 citations95

US12173078B2Dec 24, 2024

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

DYNE THERAPEUTICS INC14 citations95

US12173079B2Dec 24, 2024

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

DYNE THERAPEUTICS INC14 citations95

US12097263B2Sep 24, 2024

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC18 citations95

US12018087B2Jun 25, 2024

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject

DYNE THERAPEUTICS INC23 citations95

US12012460B2Jun 18, 2024

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

DYNE THERAPEUTICS INC22 citations95

US12005124B2Jun 11, 2024

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC23 citations95

US11911484B2Feb 27, 2024

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC28 citations95

US12239717B2Mar 4, 2025

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC13 citations94

US12239716B2Mar 4, 2025

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC13 citations94

US12144868B2Nov 19, 2024

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC14 citations94

US12144867B2Nov 19, 2024

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC14 citations94

US12102687B2Oct 1, 2024

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC17 citations94

US11986537B2May 21, 2024

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC24 citations94

US11969475B2Apr 30, 2024

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC25 citations94

US11844843B2Dec 19, 2023

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC30 citations94

US11839660B2Dec 12, 2023

Anti-transferrin receptor antibody and uses thereof

DYNE THERAPEUTICS INC30 citations94

US11633498B2Apr 25, 2023

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC37 citations94

US11931421B2Mar 19, 2024

Muscle targeting complexes and formulations for treating myotonic dystrophy

DYNE THERAPEUTICS INC26 citations92

US12329824B1Jun 17, 2025

Muscle targeting complexes and uses thereof for treating dystrophinopathies

DYNE THERAPEUTICS INC4 citations86

US12325753B2Jun 10, 2025

Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

DYNE THERAPEUTICS INC5 citations86

US12319743B2Jun 3, 2025

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

DYNE THERAPEUTICS INC5 citations86

US12280122B2Apr 22, 2025

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC5 citations86

US12128109B2Oct 29, 2024

Muscle targeting complexes and formulations for treating dystrophinopathies

DYNE THERAPEUTICS INC17 citations82

US12370264B1Jul 29, 2025

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

DYNE THERAPEUTICS INC2 citations75

US12357703B2Jul 15, 2025

Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

DYNE THERAPEUTICS INC2 citations75

US12329825B1Jun 17, 2025

Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

DYNE THERAPEUTICS INC4 citations75

US12496352B2Dec 16, 2025

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

DYNE THERAPEUTICS INC0 citations63

US12478687B2Nov 25, 2025

United states

DYNE THERAPEUTICS INC0 citations63

US12460011B2Nov 4, 2025

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering an oligonucleotide to a subject

DYNE THERAPEUTICS INC0 citations63

US12428487B2Sep 30, 2025

Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

DYNE THERAPEUTICS INC0 citations63

Showing the top 50 of 58 patents by PatentIndex Score.